학술논문

Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective
Document Type
Article
Source
In: Gynecologic Oncology. (Gynecologic Oncology, October 2022, 167(1):115-122)
Subject
Language
English
ISSN
10956859
00908258